Zolbetuximab
About
Therapy type: Immunotherapy
Therapy strategy: CLDN18.2 inhibition
Mappings
NCI Thesaurus: Zolbetuximab (coding:ncit:C85475)
RxNorm: zolbetuximab (coding:rxcui:2695869, coding:omop:1735539)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | CLDN18.2 >= 75%, HER2-negative | Adenocarcinoma of the Gastroesophageal Junction | Fluorouracil, Oxaliplatin, Zolbetuximab | |
| FDA (1) HC (1) | CLDN18.2 >= 75%, HER2-negative | Adenocarcinoma of the Gastroesophageal Junction | Capecitabine, Oxaliplatin, Zolbetuximab |